A Closer Look at Lyell Immunopharma Inc (LYEL) Stock Gains

Lyell Immunopharma Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $3.41 on 07/19/23 and the lowest value was $1.18 on 06/27/24.

52-week price history of LYEL Stock

Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Lyell Immunopharma Inc’s current trading price is -52.49% away from its 52-week high, while its distance from the 52-week low is 37.29%. The stock’s price range during the 52-week period has remained between $1.18 and $3.41. In the Healthcare sector, the company’s shares saw a trading volume of around 0.82 million for the day, which was evidently lower than the average daily volume of 1.09 million over the past three months.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Market Capitalization and Financial Performance: An In-Depth Look

Lyell Immunopharma Inc (LYEL) has experienced a quarterly decline of -22.49% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 413.00M and boasts a workforce of 224 employees.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.3066, with a change in price of -0.3100. Similarly, Lyell Immunopharma Inc recorded 1,005,002 in trading volume during the last 100 days, posting a change of -16.06%.

Examining LYEL’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for LYEL stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.09.

LYEL Stock Stochastic Average

As of today, Lyell Immunopharma Inc’s raw stochastic average for the last 50 days stands at 25.96%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 29.43%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 23.09% and 21.80%, respectively.

LYEL Stock Price Performance Analysis

Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. The index has shown a price loss of -16.49% this year. Over the last six months, there has been a stronger performance of -18.59%. The price of LYEL leaped by -39.55% during the last 30 days period. For the last 5-days stocks have improved 11.72%.

Most Popular